CUMHURIYET SCIENCE JOURNAL, vol.42, no.4, pp.775-780, 2021 (Peer-Reviewed Journal)
Cholangiocarcinoma (CCA) is a highly aggressive and invasive malignancy with a poor
diagnosis because of the resistance, relapse and limited therapy. Histone deacetylases (HDAC)
are a class of enzyme that have important roles in epigenetic modulations. These enzymes are
intensely studied and HDAC inhibitors are considered as potent anticancer agents in both solid
tumors and hematological malignancies. HDAC inhibitors can affect and induce different
mechanisms such as cell cycle arrest, differentiation, and cell death. In this study, we aim to
investigate the cytotoxic effect of Tubastatin A, which is a selective HDAC6 inhibitor, on
cholangiocarcinoma cell lines, TFK-1 and EGI-1, by MTT assay. Besides, it was aimed to
examine the impact on colony formation potential of the cells. The effect of the inhibitor on
cell cycle distribution was also examined by using flow cytometry. Tubastatin A has
significantly decreased the colony formation and changed cell cycle progression. Taken
together, our results suggest that Tubastatin A could be a potent inhibitor against
cholangiocarcinoma. On the basis of these results, further mechanistic studies are required to
elucidate the antineoplastic activity of Tubastatin A.